Advisory Committee on Immunization Practices (ACIP), 14328-14329 [2021-05216]
Download as PDF
<![CDATA[
14328
Federal Register / Vol. 86, No. 48 / Monday, March 15, 2021 / Notices
khammond on DSKJM1Z7X2PROD with NOTICES
Infrastructure Improvements for the
Nation Act; 42 U.S.C. 300j–27, Registry
for Lead Exposure and Advisory
Committee. The Secretary, Department
of Health and Human Services (HHS)
and by delegation, the Director, CDC
and Administrator, NCEH/ATSDR, are
authorized under Section 2203 of Public
Law 114–322 (42 U.S.C. 300j–27) to
review research and Federal programs
and services related to lead poisoning
and to identify effective services and
best practices for addressing and
preventing lead exposure in
communities.
The LEPAC is charged with providing
advice and guidance to the Secretary,
HHS, and the Director, CDC and
Administrator, ATSDR, on (1) reviewing
Federal programs and services available
to individual communities exposed to
lead; (2) reviewing current research on
lead exposure to identify additional
research needs; (3) reviewing and
identifying best practices, or the need
for best practices regarding lead
screening and the prevention of lead
poisoning; (4) identifying effective
services, including services relating to
healthcare, education, and nutrition for
individuals and communities affected
by lead exposure and lead poisoning,
including in consultation with, as
appropriate, the lead exposure registry
as established in Section 2203 (b) of
Public Law 114–322; and (5)
undertaking any other review or
activities that the Secretary determines
to be appropriate.
Matters To Be Considered: The agenda
will include discussions on the Federal
Lead Action Plan, American Healthy
Homes Survey II, a 40-Year National
Health and Nutritional Examination
Survey (NHANES) Analysis of lead data,
the Blood Lead Reference Value (BLRV)
Workgroup, and the 2020 Annual
LEPAC Report. Agenda items are subject
to change as priorities dictate.
Public Participation
Procedure for Oral Public Comment:
The public comment period is
scheduled on May 14, 2021, from 11:45
a.m. until 12:00 p.m. Individuals
wishing to make a comment during the
public comment period, please email
your name, organization, and phone
number by April 30, 2021, to LEPAC@
cdc.gov.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
VerDate Sep<11>2014
16:36 Mar 12, 2021
Jkt 253001
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2021–05218 Filed 3–12–21; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[Docket No. CDC–2021–0025]
Advisory Committee on Immunization
Practices (ACIP)
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice of meeting and request
for comment.
AGENCY:
In accordance with the
Federal Advisory Committee Act, the
Centers for Disease Control and
Prevention (CDC), announces the
following meeting of the Advisory
Committee on Immunization Practices
(ACIP). This meeting is open to the
public. Time will be available for public
comment.
DATES: The meeting will be held on May
5, 2021, from 11:00 a.m. to 5:00 p.m.,
EDT (times subject to change). Written
comments must be received on or before
May 5, 2021.
ADDRESSES: You may submit comments,
identified by Docket No. CDC–2020–
0025 by any of the following methods:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: Centers for Disease Control
and Prevention, 1600 Clifton Road NE,
MS H24–8, Atlanta, GA 30329–4027,
Attn: May ACIP Meeting.
Instructions: All submissions received
must include the Agency name and
Docket Number. All relevant comments
received in conformance with the
https://www.regulations.gov suitability
policy will be posted without change to
https://www.regulations.gov, including
any personal information provided. For
access to the docket to read background
documents or comments received, go to
https://www.regulations.gov.
Written public comments submitted
72 hours prior to the ACIP meeting will
be provided to ACIP members before the
meeting.
FOR FURTHER INFORMATION CONTACT:
Stephanie Thomas, ACIP Committee
Management Specialist, Centers for
SUMMARY:
PO 00000
Frm 00028
Fmt 4703
Sfmt 4703
Disease Control and Prevention,
National Center for Immunization and
Respiratory Diseases, 1600 Clifton Road
NE, MS–H24–8, Atlanta, GA 30329–
4027; Telephone: 404–639–8367; Email:
ACIP@cdc.gov.
SUPPLEMENTARY INFORMATION:
Purpose: The committee is charged
with advising the Director, CDC, on the
use of immunizing agents. In addition,
under 42 U.S.C. 1396s, the committee is
mandated to establish and periodically
review and, as appropriate, revise the
list of vaccines for administration to
vaccine-eligible children through the
Vaccines for Children (VFC) program,
along with schedules regarding dosing
interval, dosage, and contraindications
to administration of vaccines. Further,
under provisions of the Affordable Care
Act, section 2713 of the Public Health
Service Act, immunization
recommendations of the ACIP that have
been approved by the Director of the
Centers for Disease Control and
Prevention and appear on CDC
immunization schedules must be
covered by applicable health plans.
Matters To Be Considered: The agenda
will include discussions on dengue
vaccine and rabies vaccines. No
recommendation votes are scheduled.
Agenda items are subject to change as
priorities dictate. For more information
on the meeting agenda visit https://
www.cdc.gov/vaccines/acip/meetings/
meetings-info.html.
Meeting Information: The meeting
will be webcast live via the World Wide
Web; for more information on ACIP
please visit the ACIP website: https://
www.cdc.gov/vaccines/acip/.
Public Participation
Interested persons or organizations
are invited to participate by submitting
written views, recommendations, and
data. Please note that comments
received, including attachments and
other supporting materials, are part of
the public record and are subject to
public disclosure. Comments will be
posted on https://www.regulations.gov.
Therefore, do not include any
information in your comment or
supporting materials that you consider
confidential or inappropriate for public
disclosure. If you include your name,
contact information, or other
information that identifies you in the
body of your comments, that
information will be on public display.
CDC will review all submissions and
may choose to redact, or withhold,
submissions containing private or
proprietary information such as Social
Security numbers, medical information,
inappropriate language, or duplicate/
near duplicate examples of a mass-mail
E:\FR\FM\15MRN1.SGM
15MRN1
Federal Register / Vol. 86, No. 48 / Monday, March 15, 2021 / Notices
campaign. CDC will carefully consider
all comments submitted into the docket.
Written Public Comment: Written
comments must be received on or before
May 5, 2021.
Oral Public Comment: This meeting
will include time for members of the
public to make an oral comment. Oral
public comment will occur before any
scheduled votes including all votes
relevant to the ACIP’s Affordable Care
Act and Vaccines for Children Program
roles. Priority will be given to
individuals who submit a request to
make an oral public comment before the
meeting according to the procedures
below.
Procedure for Oral Public Comment:
All persons interested in making an oral
public comment at the May ACIP
meeting must submit a request at https://
www.cdc.gov/vaccines/acip/meetings/
no later than 11:59 p.m., EDT, April 30,
2021, according to the instructions
provided.
If the number of persons requesting to
speak is greater than can be reasonably
accommodated during the scheduled
time, CDC will conduct a lottery to
determine the speakers for the
scheduled public comment session.
CDC staff will notify individuals
regarding their request to speak by email
by May 3, 2021. To accommodate the
significant interest in participation in
the oral public comment session of
ACIP meetings, each speaker will be
limited to 3 minutes, and each speaker
may only speak once per meeting.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
khammond on DSKJM1Z7X2PROD with NOTICES
[FR Doc. 2021–05216 Filed 3–12–21; 8:45 am]
BILLING CODE 4163–18–P
VerDate Sep<11>2014
16:36 Mar 12, 2021
Jkt 253001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[CMS–4195–FN]
Medicare Program; Approved Renewal
of Deeming Authority of the National
Committee for Quality Assurance for
Medicare Advantage Health
Maintenance Organizations and
Preferred Provider Organizations
Centers for Medicare &
Medicaid Services (CMS), HHS.
ACTION: Final notice.
AGENCY:
This final notice announces
our decision to renew the Medicare
Advantage ‘‘deeming authority’’ of the
National Committee for Quality
Assurance (NCQA) for health
maintenance organizations and
preferred provider organizations for a
term of 6 years.
DATES: The decision announced in this
final notice is effective December 30,
2020 through December 30, 2026.
FOR FURTHER INFORMATION CONTACT: Greg
McDonald, (410) 786–8941.
SUPPLEMENTARY INFORMATION:
SUMMARY:
I. Background
Under the Medicare program, eligible
beneficiaries may receive covered
services through a Medicare Advantage
(MA) organization that contracts with
CMS. The regulations specifying the
Medicare requirements that must be met
for a Medicare Advantage Organization
(MAO) to enter into a contract with
CMS are located at 42 CFR part
422.These regulations implement Part C
of Title XVIII of the Social Security Act
(the Act), which specifies the services
that an MAO must provide and the
requirements that the organization must
meet to be an MA contractor. Other
relevant sections of the Act are Parts A
and B of Title XVIII and Part A of Title
XI pertaining to the provision of
services by Medicare certified providers
and suppliers. Generally, for an entity to
be an MA organization, the organization
must be licensed by the state as a risk
bearing organization, as set forth in 42
CFR part 422.
As a method of assuring compliance
with certain Medicare requirements, an
MA organization may choose to become
accredited by a CMS-approved
accrediting organization (AO). By virtue
of its accreditation by a CMS-approved
AO, the MA organization may be
‘‘deemed’’ compliant in one or more
requirements set forth in section
1852(e)(4)(B) of the Act. For CMS to
PO 00000
Frm 00029
Fmt 4703
Sfmt 4703
14329
recognize an AO’s accreditation
program as establishing an MA plan’s
compliance with our requirements, the
AO must prove to CMS that its
standards are at least as stringent as
Medicare requirements for MA
organizations. MA organizations that are
licensed as health maintenance
organizations (HMOs) or preferred
provider organizations (PPOs) and are
accredited by an approved accrediting
organization may receive, at their
request, deemed status for CMS
requirements with respect to the
deemable areas. At this time,
recognition of accreditation does not
include the Part D areas of review set
out at 42 CFR 423.165(b). AOs that
apply for MA deeming authority are
generally recognized by the health care
industry as entities that accredit HMOs
and PPOs. As we specify at
§ 422.157(b)(2)(ii), the term for which an
AO may be approved by CMS may not
exceed 6 years. For continuing approval,
the AO must apply to CMS to renew
their deeming authority for a subsequent
approval period.
The National Committee for Quality
Assurance (NCQA) was last approved as
a CMS-approved accreditation
organization for MA deeming of HMOs
and PPOs for a 6-year term beginning on
October 19, 2014, and that term lapsed
on October 18, 2020, prior to our
decision on its renewal application.
NCQA did not accredit or re-accredit
any HMOs or PPOs for MA deeming
between that date and December 30,
2020, the effective date of its reapproval. On May 22, 2020, NCQA
submitted an application to renew its
deeming authority. On that same date,
NCQA submitted materials requested by
CMS that included information
intended to address the requirements set
out at § 422.158(a) and (b) that are
prerequisites for receiving approval of
its accreditation program from CMS.
CMS subsequently requested that
additional materials and revisions be
submitted by NCQA to satisfy these
requirements. NCQA submitted all the
necessary materials to enable us to make
a determination concerning its request
for approval as an accreditation
organization, and the renewal
application was determined to be
complete on August 28, 2020.
II. Provisions of the Proposed Notice
In the November 9, 2020 Federal
Register (85 FR 71346), we published a
proposed notice announcing NCQA’s
request to renew its Medicare
Advantage deeming authority for HMOs
and PPOs. In the November 9, 2020
proposed notice, we detailed our
evaluation criteria. Under section
E:\FR\FM\15MRN1.SGM
15MRN1
]]>Agencies
[Federal Register Volume 86, Number 48 (Monday, March 15, 2021)]
[Notices]
[Pages 14328-14329]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-05216]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[Docket No. CDC-2021-0025]
Advisory Committee on Immunization Practices (ACIP)
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice of meeting and request for comment.
-----------------------------------------------------------------------
SUMMARY: In accordance with the Federal Advisory Committee Act, the
Centers for Disease Control and Prevention (CDC), announces the
following meeting of the Advisory Committee on Immunization Practices
(ACIP). This meeting is open to the public. Time will be available for
public comment.
DATES: The meeting will be held on May 5, 2021, from 11:00 a.m. to 5:00
p.m., EDT (times subject to change). Written comments must be received
on or before May 5, 2021.
ADDRESSES: You may submit comments, identified by Docket No. CDC-2020-
0025 by any of the following methods:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments.
Mail: Centers for Disease Control and Prevention, 1600
Clifton Road NE, MS H24-8, Atlanta, GA 30329-4027, Attn: May ACIP
Meeting.
Instructions: All submissions received must include the Agency name
and Docket Number. All relevant comments received in conformance with
the https://www.regulations.gov suitability policy will be posted
without change to https://www.regulations.gov, including any personal
information provided. For access to the docket to read background
documents or comments received, go to https://www.regulations.gov.
Written public comments submitted 72 hours prior to the ACIP
meeting will be provided to ACIP members before the meeting.
FOR FURTHER INFORMATION CONTACT: Stephanie Thomas, ACIP Committee
Management Specialist, Centers for Disease Control and Prevention,
National Center for Immunization and Respiratory Diseases, 1600 Clifton
Road NE, MS-H24-8, Atlanta, GA 30329-4027; Telephone: 404-639-8367;
Email: [email protected].
SUPPLEMENTARY INFORMATION:
Purpose: The committee is charged with advising the Director, CDC,
on the use of immunizing agents. In addition, under 42 U.S.C. 1396s,
the committee is mandated to establish and periodically review and, as
appropriate, revise the list of vaccines for administration to vaccine-
eligible children through the Vaccines for Children (VFC) program,
along with schedules regarding dosing interval, dosage, and
contraindications to administration of vaccines. Further, under
provisions of the Affordable Care Act, section 2713 of the Public
Health Service Act, immunization recommendations of the ACIP that have
been approved by the Director of the Centers for Disease Control and
Prevention and appear on CDC immunization schedules must be covered by
applicable health plans.
Matters To Be Considered: The agenda will include discussions on
dengue vaccine and rabies vaccines. No recommendation votes are
scheduled. Agenda items are subject to change as priorities dictate.
For more information on the meeting agenda visit https://www.cdc.gov/vaccines/acip/meetings/meetings-info.html.
Meeting Information: The meeting will be webcast live via the World
Wide Web; for more information on ACIP please visit the ACIP website:
https://www.cdc.gov/vaccines/acip/.
Public Participation
Interested persons or organizations are invited to participate by
submitting written views, recommendations, and data. Please note that
comments received, including attachments and other supporting
materials, are part of the public record and are subject to public
disclosure. Comments will be posted on https://www.regulations.gov.
Therefore, do not include any information in your comment or supporting
materials that you consider confidential or inappropriate for public
disclosure. If you include your name, contact information, or other
information that identifies you in the body of your comments, that
information will be on public display. CDC will review all submissions
and may choose to redact, or withhold, submissions containing private
or proprietary information such as Social Security numbers, medical
information, inappropriate language, or duplicate/near duplicate
examples of a mass-mail
[[Page 14329]]
campaign. CDC will carefully consider all comments submitted into the
docket.
Written Public Comment: Written comments must be received on or
before May 5, 2021.
Oral Public Comment: This meeting will include time for members of
the public to make an oral comment. Oral public comment will occur
before any scheduled votes including all votes relevant to the ACIP's
Affordable Care Act and Vaccines for Children Program roles. Priority
will be given to individuals who submit a request to make an oral
public comment before the meeting according to the procedures below.
Procedure for Oral Public Comment: All persons interested in making
an oral public comment at the May ACIP meeting must submit a request at
https://www.cdc.gov/vaccines/acip/meetings/ no later than 11:59 p.m.,
EDT, April 30, 2021, according to the instructions provided.
If the number of persons requesting to speak is greater than can be
reasonably accommodated during the scheduled time, CDC will conduct a
lottery to determine the speakers for the scheduled public comment
session. CDC staff will notify individuals regarding their request to
speak by email by May 3, 2021. To accommodate the significant interest
in participation in the oral public comment session of ACIP meetings,
each speaker will be limited to 3 minutes, and each speaker may only
speak once per meeting.
The Director, Strategic Business Initiatives Unit, Office of the
Chief Operating Officer, Centers for Disease Control and Prevention,
has been delegated the authority to sign Federal Register notices
pertaining to announcements of meetings and other committee management
activities, for both the Centers for Disease Control and Prevention and
the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2021-05216 Filed 3-12-21; 8:45 am]
BILLING CODE 4163-18-P
